+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy), by Application, by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 165 Pages
  • April 2022
  • Region: Global
  • Grand View Research
  • ID: 4621710
The global nuclear medicine market size is expected to reach USD 24.4 billion by 2030, expanding at a CAGR of 13.0% from 2022 to 2030. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market. For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer.



According to the Pan American Health Organization (PAHO), in 2022, globally around 20 million new cases of cancer are estimated to be diagnosed, and around 10 million deaths occurred due to this disease. Factors like changing lifestyle, unhealthy diet, and less awareness about oral hygiene in low and middle-income countries is the most common cause of the prevalence of cancer.

Increasing adoption of nuclear medicine products in diagnosis and the approval of new generators to help increase the supply of radionuclides is expected to drive growth. For instance, in November 2021, EZAG received the Brazilian Health Authority Regulatory Agency’s (ANVISA) approval for GalliaPharm in Brazil. It is a gallium-68 generator used to extract the positron-emitting isotope of gallium from a source of decaying germanium-68 for making G68 dotatate injection. This is the first and only gallium generator approved for pharmaceutical use in Brazil. The approval of such products contributes to the market growth in developing markets.

In light of the COVID-19 pandemic, the market was moderately impacted. A survey was conducted for reactor-based medical isotopes by International Atomic Energy Agency (IAEA) during the second quarter of 2020 to assess the continuity of the supply chain during the COVID-19 crisis. It was revealed that major producers continued with production in line with IAEA safety standards, as their operations were categorized as essential by their respective governments.

Nuclear Medicine Market Report Highlights

  • by product type, the SPECT segment held the largest share of the diagnostics market due to low cost, high accuracy, and wide usage in different applications.
  • The PET segment is expected to grow lucratively over the forecast period due to the approval & launch of new products such as PYLARIFY PET imaging agent for prostate cancer.
  • by application, the oncology segment dominated the market in 2021 with a share of 42.06%.
  • North America dominated the global market in 2021, owing to increased awareness about current treatment therapies, favorable reimbursement policies, and improved patient affordability.
  • The Asia Pacific region is expected to grow considerably in the future due to the rising prevalence of chronic diseases, rising geriatric population, and approval of new products during the forecast period.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Nuclear Medicine Market

What is the estimated value of the Global Nuclear Medicine Market?

The Global Nuclear Medicine Market was estimated to be valued at $8.9 Billion in 2022.

What is the growth rate of the Global Nuclear Medicine Market?

The growth rate of the Global Nuclear Medicine Market is 13.0%, with an estimated value of $24.4 Billion by 2030.

What is the forecasted size of the Global Nuclear Medicine Market?

The Global Nuclear Medicine Market is estimated to be worth $24.4 Billion by 2030.

Who are the key companies in the Global Nuclear Medicine Market?

Key companies in the Global Nuclear Medicine Market include Eckert & Ziegler, Mallinckrodt, Curium Pharma, General Electric, Jubilant Life Sciences Ltd., Bracco Imaging S.P.A., Nordion (Canada), Inc., the Institute for Radioelements (Ire and Be).

Table of Contents

Chapter 1 Research Methodology
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List Of Secondary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Definitions
Chapter 4 Industry Outlook
4.1 Market Variable Analysis
4.1.1 Rising Incidence Of Cancer and Cardiovascular Diseases
4.1.2 Increasing Application Of Radiopharmaceuticals/Nuclear Medicine
4.1.3 Growing Demand For Accurate Diagnostic Methods
4.1.4 Market Restraint Analysis
4.1.4.1 Stringent Regulations Pertaining To Production, Storage, & Usage
4.1.4.2 High Costs Associated With Diagnostics & Therapeutic Procedures
4.1.5 Swot Analysis; by Factor (Political & Legal, Economic and Technological)
4.1.6 Porter’s Five Forces Analysis
4.1.7 Value Chain Analysis
4.2 List Of Factors/Regulations by Country
4.2.1 North America
4.2.1.1 U.S.
4.2.1.2 Canada
4.2.2 Europe
4.2.3 Asia Pacific
4.2.3.1 China
4.2.3.2 Japan
4.2.3.3 India
4.2.3.4 Australia/New Zealand
4.2.3.5 South Korea
4.2.3.6 Singapore
4.2.3.7 Malaysia
4.2.3.8 Philippines
4.2.4 Latin America
4.2.4.1 Brazil
4.2.4.2 Mexico
4.2.4.3 Argentina
4.2.5 Middle East & Africa
4.2.5.1 South Africa
4.2.5.2 Gcc
4.3 Production Process and Trends
4.3.1 Production Of Molybdenum-99 (Spect Radioisotopes)
4.3.2 Spect Radioisotopes Trends
4.3.3 Pet Radioisotopes Trends
4.3.3.1 Production Of Pet Radioisotopes
4.3.4 Therapeutic Radioisotopes Trends
4.3.4.1 Production Process and Trends
4.4 Radiopharmaceuticals Market-Covid-19 Impact
4.5 Pipeline Analysis
Chapter 5 Competitive Analysis
5.1 Vendor Landscape
5.1.1 List Of Key Distributors and Channel Partners
5.1.2 Key Company Market Share Analysis, 2021
5.2 Public Companies
5.2.1 Company Market Position Analysis
5.2.2 Competitive Dashboard Analysis
5.3 Private Companies
5.3.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
5.3.2 Regional Network Map
Chapter 6 Product Business Analysis
6.1 Radiopharmaceuticals Market: Product Movement Analysis
6.2 Diagnostic Products
6.2.1 Diagnostic Products Market Estimates and Forecast, 2018-2030 (USD Million)
6.2.1.1 Spect
6.2.1.1.1 Spect Products Market Estimates and Forecast, 2018-2030 (USD Million)
6.2.1.1.2 Tc-99m
6.2.1.1.3 Tc-99m Market Estimates and Forecast, 2018-2030 (USD Million)
6.2.1.1.4 Tl-201
6.2.1.1.5 Tl-201 Market Estimates and Forecast, 2018-2030 (USD Million)
6.2.1.1.6 Ga-67
6.2.1.1.7 Ga-67 Market Estimates and Forecast, 2018-2030 (USD Million)
6.2.1.1.8 I-123
6.2.1.1.9 I-123 Market Estimates and Forecast, 2018-2030 (USD Million)
6.2.1.1.10 Other Spect Products
6.2.1.1.11 Other Spect Products Market Estimates and Forecast, 2018-2030 (USD Million)
6.2.1.2 Pet
6.2.1.2.1 Pet Products Market Estimates and Forecast, 2018-2030 (USD Million)
6.2.1.2.2 F-18
6.2.1.2.3 F-18 Market Estimates and Forecast, 2018-2030 (USD Million)
6.2.1.2.4 Sr-82/Rb-82
6.2.1.2.5 Sr-82/Rb-82 Market Estimates and Forecast, 2018-2030 (USD Million)
6.2.1.2.6 Other Pet Products
6.2.1.2.7 Other Pet Products Market Estimates and Forecast, 2018-2030 (USD Million)
6.3 Therapeutic Products
6.3.1 Therapeutic Products Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.2 Alpha Emitters
6.3.2.1 Alpha Emitters Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.2.1.1 Ra-223
6.3.2.1.1.1 Ra-223 Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.3 Beta Emitters
6.3.3.1 Beta Emitters Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.3.2 I-131
6.3.3.2.1 I-131 Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.3.3 Y-90
6.3.3.3.1 Y-90 Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.3.4 Sm-153
6.3.3.4.1 Sm-153 Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.3.5 Re-186
6.3.3.5.1 Re-186 Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.3.6 Lu-177
6.3.3.6.1 Lu-177 Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.3.7 Other Beta Emitters
6.3.3.7.1 Other Beta Emitters Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.4 Brachytherapy
6.3.4.1 Brachytherapy Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.4.2 Cesium-131
6.3.4.2.1 Cesium-131 Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.4.3 Iodine-125
6.3.4.3.1 Iodine-125 Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.4.4 Palladium-103
6.3.4.4.1 Palladium-103 Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.4.5 Iridium-192
6.3.4.5.1 Iridium-192 Market Estimates and Forecast, 2018-2030 (USD Million)
6.3.4.6 Other Brachytherapy Products
6.3.4.6.1 Other Brachytherapy Products Market Estimates and Forecast, 2018-2030 (USD Million)
Chapter 7 Application Mode Business Analysis
7.1 Radiopharmaceuticals: Application Movement Analysis
7.1.1 Cardiology
7.1.1.1 Cardiology Market Estimates and Forecast, 2018-2030 (USD Million)
7.1.2 Neurology
7.1.2.1 Neurology Market Estimates and Forecast, 2018-2030 (USD Million)
7.1.3 Oncology
7.1.3.1 Oncology Market Estimates and Forecast, 2018-2030 (USD Million)
7.1.4 Thyroid
7.1.4.1 Thyroid Market Estimates and Forecast, 2018-2030 (USD Million)
7.1.5 Lymphoma
7.1.5.1 Lymphoma Market Estimates and Forecast, 2018-2030 (USD Million)
7.1.6 Bone Metastasis
7.1.6.1 Bone Metastasis Market Estimates and Forecast, 2018-2030 (USD Million)
7.1.7 Endocrine Tumor
7.1.7.1 Endocrine Tumor Market Estimates and Forecast, 2018-2030 (USD Million)
7.1.8 Other Application
7.1.8.1 Other Market Estimates and Forecast, 2018-2030 (USD Million)
Chapter 8 Regional Business Analysis
8.1 Radiopharmaceuticals Market: Regional Movement Analysis
8.2 North America
8.2.1 North America Market Estimates and Forecast, 2018-2030 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. Market Estimates and Forecast, 2018-2030 (USD Million)
8.2.3 Canada
8.2.3.1 Canada Market Estimates and Forecast, 2018-2030 (USD Million)
8.3 Europe
8.3.1 Europe Market Estimates and Forecast, 2018-2030 (USD Million)
8.3.2 U.K.
8.3.2.1 U.K. Market Estimates and Forecast, 2018-2030 (USD Million)
8.3.3 Germany
8.3.3.1 Germany Market Estimates and Forecast, 2018-2030 (USD Million)
8.3.4 Italy
8.3.4.1 Italy Market Estimates and Forecast, 2018-2030 (USD Million)
8.3.5 Spain
8.3.5.1 Spain Market Estimates and Forecast, 2018-2030 (USD Million)
8.3.6 France
8.3.6.1 France Market Estimates and Forecast, 2018-2030 (USD Million)
8.3.7 Russia
8.3.7.1 Russia Market Estimates and Forecast, 2018-2030 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Market Estimates and Forecast, 2018-2030 (USD Million)
8.4.2 Japan
8.4.2.1 Japan Market Estimates and Forecast, 2018-2030 (USD Million)
8.4.3 China
8.4.3.1 China Market Estimates and Forecast, 2018-2030 (USD Million)
8.4.4 India
8.4.4.1 India Market Estimates and Forecast, 2018-2030 (USD Million)
8.4.5 Singapore
8.4.5.1 Singapore Market Estimates and Forecast, 2018-2030 (USD Million)
8.4.6 Australia
8.4.6.1 Australia Market Estimates and Forecast, 2018-2030 (USD Million)
8.4.7 South Korea
8.4.7.1 South Korea Market Estimates and Forecast, 2018-2030 (USD Million)
8.5 Latin America
8.5.1 Latin America Market Estimates and Forecast, 2018-2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil Market Estimates and Forecast, 2018-2030 (USD Million)
8.5.3 Mexico
8.5.3.1 Mexico Market Estimates and Forecast, 2018-2030 (USD Million)
8.5.4 Argentina
8.5.4.1 Argentina Market Estimates and Forecast, 2018-2030 (USD Million)
8.6 Middle East & Africa
8.6.1 Middle-East and Africa Market Estimates and Forecast, 2018-2030 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa Market Estimates and Forecast, 2018-2030 (USD Million)
8.6.3 Saudi Arabia
8.6.3.1 Saudia Arabia Market Estimates and Forecast, 2018-2030 (USD Million)
8.6.4 Uae
8.6.4.1 Uae Market Estimates and Forecast, 2018-2030 (USD Million)
Chapter 9 Company Profiles
9.1 ECKERT & ZIEGLER
9.1.1 Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.2 MALLINCKRODT
9.2.1 Company overview
9.3 CURIUM PHARMA
9.3.1 Company overview
9.3.2 Product benchmarking
9.3.3 Strategic initiatives
9.4 GENERAL ELECTRIC
9.4.1 Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.5 JUBILANT LIFE SCIENCES LTD.
9.5.1 Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.6 BRACCO IMAGING S.P.A.
9.6.1 Company overview
9.6.2 Product benchmarking
9.6.3 Strategic initiatives
9.7 NORDION (CANADA), INC.
9.7.1 Company overview
9.7.2 Product benchmarking
9.7.3 Strategic initiatives
9.8 THE INSTITUTE FOR RADIOELEMENTS (IRE-IRE ELIT-BE)
9.8.1 Company overview
9.8.2 Product benchmarking
9.8.3 Strategic initiatives
9.9 AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANIZATION (ANSTO)
9.9.1 Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.10 NTP RADIOISOTOPES SOC LTD.
9.10.1 Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.11 ECZACIBASI-MONROL
9.11.1 Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.12 LANTHEUS MEDICAL IMAGING, INC.
9.12.1 Company overview
9.12.2 Financial overview
9.12.3 Product benchmarking
9.12.4 Strategic initiatives

Samples

Loading
LOADING...

Companies Mentioned

  • Eckert & Ziegler
  • Mallinckrodt
  • Curium Pharma
  • General Electric
  • Jubilant Life Sciences Ltd.
  • Bracco Imaging S.P.A.
  • Nordion (Canada), Inc.
  • the Institute for Radioelements (Ire-Ire Elit-Be)
  • Australian Nuclear Science & Technology Organization (Ansto)
  • Ntp Radioisotopes Soc Ltd.
  • Eczacibaşi-Monrol
  • Lantheus Medical Imaging, Inc.

Methodology

Loading
LOADING...